Justin K Banerdt1,2,3, Kondwelani Mateyo4,5, Li Wang6, Christopher J Lindsell6, Elisabeth D Riviello7,8, Deanna Saylor4,5,9, Douglas C Heimburger4,10,11, E Wesley Ely3,10,12. 1. Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America. 2. Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America. 3. Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America. 4. University of Zambia School of Medicine, Lusaka, Zambia. 5. University Teaching Hospital, Lusaka, Zambia. 6. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America. 7. Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America. 8. Harvard Medical School, Boston, Massachusetts, United States of America. 9. Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America. 10. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America. 11. Vanderbilt Institute for Global Health, Nashville, Tennessee, United States of America. 12. Tennessee Valley Veteran's Affairs Geriatric Research Education Clinical Center (GRECC), Nashville, Tennessee, United States of America.
Abstract
OBJECTIVE: To study the epidemiology and outcomes of delirium among hospitalized patients in Zambia. METHODS: We conducted a prospective cohort study at the University Teaching Hospital in Lusaka, Zambia, from October 2017 to April 2018. The primary exposure was delirium duration over the initial 3 days of hospitalization, assessed daily using the Brief Confusion Assessment Method. The primary outcome was 6-month mortality. Secondary outcomes included 6-month disability, evaluated using the World Health Organization Disability Assessment Schedule 2.0. FINDINGS: 711 adults were included (median age, 39 years; 461 men; 459 medical, 252 surgical; 323 with HIV). Delirium prevalence was 48.5% (95% CI, 44.8%-52.3%). 6-month mortality was higher for delirious participants (44.6% [39.3%-50.1%]) versus non-delirious participants (20.0% [15.4%-25.2%]; P < .001). After adjusting for covariates, delirium duration independently predicted 6-month mortality and disability with a significant dose-response association between number of days with delirium and odds of worse clinical outcome. Compared to no delirium, presence of 1, 2 or 3 days of delirium resulted in odds ratios for 6-month mortality of 1.43 (95% CI, 0.73-2.80), 2.20 (1.07-4.51), and 3.92 (2.24-6.87), respectively (P < .001). Odds of 6-month disability were 1.20 (0.70-2.05), 1.73 (0.95-3.17), and 2.80 (1.78-4.43), respectively (P < .001). CONCLUSION: Among hospitalized medical and surgical patients in Zambia, delirium prevalence was high and delirium duration independently predicted mortality and disability at 6 months. This work lays the foundation for prevention, detection, and management of delirium in low-income countries. Long-term follow up of outcomes of critical illness in resource-limited settings appears feasible using the WHO Disability Assessment Schedule.
OBJECTIVE: To study the epidemiology and outcomes of delirium among hospitalized patients in Zambia. METHODS: We conducted a prospective cohort study at the University Teaching Hospital in Lusaka, Zambia, from October 2017 to April 2018. The primary exposure was delirium duration over the initial 3 days of hospitalization, assessed daily using the Brief Confusion Assessment Method. The primary outcome was 6-month mortality. Secondary outcomes included 6-month disability, evaluated using the World Health Organization Disability Assessment Schedule 2.0. FINDINGS: 711 adults were included (median age, 39 years; 461 men; 459 medical, 252 surgical; 323 with HIV). Delirium prevalence was 48.5% (95% CI, 44.8%-52.3%). 6-month mortality was higher for delirious participants (44.6% [39.3%-50.1%]) versus non-deliriousparticipants (20.0% [15.4%-25.2%]; P < .001). After adjusting for covariates, delirium duration independently predicted 6-month mortality and disability with a significant dose-response association between number of days with delirium and odds of worse clinical outcome. Compared to no delirium, presence of 1, 2 or 3 days of delirium resulted in odds ratios for 6-month mortality of 1.43 (95% CI, 0.73-2.80), 2.20 (1.07-4.51), and 3.92 (2.24-6.87), respectively (P < .001). Odds of 6-month disability were 1.20 (0.70-2.05), 1.73 (0.95-3.17), and 2.80 (1.78-4.43), respectively (P < .001). CONCLUSION: Among hospitalized medical and surgical patients in Zambia, delirium prevalence was high and delirium duration independently predicted mortality and disability at 6 months. This work lays the foundation for prevention, detection, and management of delirium in low-income countries. Long-term follow up of outcomes of critical illness in resource-limited settings appears feasible using the WHO Disability Assessment Schedule.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Christopher W Seymour; Vincent X Liu; Theodore J Iwashyna; Frank M Brunkhorst; Thomas D Rea; André Scherag; Gordon Rubenfeld; Jeremy M Kahn; Manu Shankar-Hari; Mervyn Singer; Clifford S Deutschman; Gabriel J Escobar; Derek C Angus Journal: JAMA Date: 2016-02-23 Impact factor: 56.272
Authors: Douglas L Leslie; Ying Zhang; Theodore R Holford; Sidney T Bogardus; Linda S Leo-Summers; Sharon K Inouye Journal: Arch Intern Med Date: 2005-07-25
Authors: Jane S Saczynski; Edward R Marcantonio; Lien Quach; Tamara G Fong; Alden Gross; Sharon K Inouye; Richard N Jones Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: E Wesley Ely; Ayumi Shintani; Brenda Truman; Theodore Speroff; Sharon M Gordon; Frank E Harrell; Sharon K Inouye; Gordon R Bernard; Robert S Dittus Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: Jin H Han; Amanda Wilson; Eduard E Vasilevskis; Ayumi Shintani; John F Schnelle; Robert S Dittus; Amy J Graves; Alan B Storrow; John Shuster; E Wesley Ely Journal: Ann Emerg Med Date: 2013-07-31 Impact factor: 5.721
Authors: Morgan L Prust; Amir Mbonde; Clio Rubinos; Gentle S Shrestha; Morenikeji Komolafe; Deanna Saylor; Halinder S Mangat Journal: Neurocrit Care Date: 2022-07-16 Impact factor: 3.532